After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, PLRX falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Pliant Therapeutics Inc is $680.35M. A total of 0.64 million shares were traded on the day, compared to an average of 533.59K shares.
In the most recent transaction, Coulie Bernard sold 52,419 shares of PLRX for 11.20 per share on Jan 17 ’25. After the transaction, the President and CEO now owns 430,517 company shares. In a previous transaction on Jan 17 ’25, Cummings Keith Lamont sold 20,148 shares at 11.20 per share. PLRX shares that Chief Financial Officer owns now total 262,608.
Among the insiders who sold shares, Hull Hans disposed of 15,936 shares on Jan 17 ’25 at a per-share price of $11.20. This resulted in the Chief Business Officer holding 211,558 shares of PLRX after the transaction. In another insider transaction, Lefebvre Eric sold 18,478 shares at $11.20 per share on Jan 17 ’25. Company shares held by the Chief Medical Officer now total 194,574.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, PLRX has a high of $18.46 and a low of $10.22.
As of this writing, PLRX has an earnings estimate of -$0.98 per share for the current quarter. EPS was calculated based on a consensus of 10.0 estimates, with a high estimate of -$0.92 per share and a lower estimate of -$1.05.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. PLRX’s latest balance sheet shows that the firm has $200.60M in Cash & Short Term Investments as of fiscal 2021. There were $7.19M in debt and $16.83M in liabilities at the time. Its Book Value Per Share was $5.68, while its Total Shareholder’s Equity was $199.06M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PLRX is Buy with a score of 4.85.
